Tcelltech GmbH develops a universal personalized adoptive cell therapy platform, UNIPACT, utilizing a high-performance gene expression DNA vector platform and an AI bioinformatics system to identify reactive T cell receptors. This technology enables the rapid generation of patient-specific T cell therapies, addressing the urgent need for effective treatments against aggressive cancers.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack the specificity needed to target tumor cells effectively, leading to significant side effects and limited efficacy, especially in aggressive cancers. Personalized adoptive cell therapies are promising but face challenges in rapidly identifying and generating patient-specific T cell receptors (TCRs) that can recognize and eliminate cancer cells.
Solution
Tcelltech GmbH is developing UNIPACT, a universal personalized adoptive cell therapy platform designed to accelerate the creation of patient-specific T cell therapies. The platform combines a high-performance gene expression DNA vector platform (nanoSMAR) with an AI bioinformatics system (selecTCR) to identify reactive T cell receptors. This approach aims to enable the rapid generation of effective treatments against a wide range of cancers by precisely targeting and eliminating tumor cells while minimizing off-target effects.
Target Audience
The primary target audience includes cancer patients with aggressive or treatment-resistant tumors, as well as oncologists and medical centers specializing in personalized cancer therapies and adoptive cell transfer.
Features
- nanoSMAR: A high-performance gene expression DNA vector platform for efficient and targeted delivery of therapeutic genes into T cells.
- selecTCR: An AI bioinformatics platform that identifies reactive T cell receptors with high specificity for cancer antigens.
- Rapid TCR identification: Accelerates the process of identifying patient-specific TCRs, reducing the time required to develop personalized therapies.
- Personalized T cell therapies: Enables the creation of adoptive cell therapies tailored to individual patients and their specific cancer profiles.